Along the same line, mice null for both p15Ink4b and p16Ink4a/Arf exhibited a broader tumor spectrum than mice deficient for p16Ink4a/Arf alone (Krimpenfort et al., 2007). This evidence concerns the gene CDKN2A and neoplasm.